Clinical Trial

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-10-08 -> 2027-10-08 2026-08-12
minor Completion pushed: 2026-10-08 -> 2027-10-08 2026-08-12
Trial Details
NCT Number NCT05090358
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: New York University
Conditions Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Enrollment 15 participants
Start Date 2021-10-08
Primary Completion 2027-10-08 (estimated)
Study Completion 2027-10-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-11